{"id":597402,"date":"2022-04-25T21:46:01","date_gmt":"2022-04-25T21:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=597402"},"modified":"2022-04-25T21:46:01","modified_gmt":"2022-04-25T21:46:01","slug":"emphysema-market-size-share-and-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-mereo-biopharma-glaxosmithkline-united-therapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/emphysema-market-size-share-and-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-mereo-biopharma-glaxosmithkline-united-therapeutics-and-others_597402.html","title":{"rendered":"Emphysema Market Size, Share and Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies &#8211; Mereo BioPharma, GlaxoSmithKline, United Therapeutics, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Emphysema Market Size, Share and Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies - Mereo BioPharma, GlaxoSmithKline, United Therapeutics, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Emphysema Market Size, Share and Trends Analysis, Therapeutics Pipeline Outlook, and Epidemiology Insights 2032 | Key Companies - Mereo BioPharma, GlaxoSmithKline, United Therapeutics, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Emphysema Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Emphysema Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Emphysema market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Emphysema Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/5499fb046393e6bc7fdb53a2cc98a568.jpg\" alt=\"Emphysema Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">E<em>mphysema is one of the diseases that comprise COPD (chronic obstructive pulmonary disease). COPD is a group of lung diseases that make it hard to breathe and get worse over time. According to American Lung Association, Emphysema develops over time and involves the gradual damage of lung tissue, specifically the destruction of the alveoli (tiny air sacs).<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Emphysema cannot be cured, however, many treatments are available to help manage symptoms. Bronchodilator medications relax the muscles, anti-inflammatory medication can reduce airway inflammation, and oxygen therapy can assist patients who need help breathing. In extreme situations, lung volume reduction surgery can relieve pressure by removing a portion of diseased lung tissue.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Emphysema Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The prevalence of emphysema in the United States is approximately 14 million, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is slightly less for white female smokers and African Americans (Pahal et al., 2020).<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>According to Pahal et al. (2020), smokers are more likely to present with Emphysema than non-smokers.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>A rare hereditary autosomal recessive disease, alpha one antitrypsin deficiency, can also lead to emphysema and liver abnormalities. However, it only contributes to 1% to 2% of cases of COPD.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>According to the Centers for Disease Control and Prevention, the number of adults who have ever been diagnosed with emphysema in the United States was around 3.8 million in 2016.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/emphysema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Emphysema Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Emphysema Market Size is expected to increase during the forecast period owing to the rising cases in the 7MM and the launch of the emerging therapies. Better diagnostic services and understanding of the disease are also anticipated to boost the therapeutic market growth in the coming years.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Emphysema market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Emphysema market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights into the historical and current <strong>Emphysema patient pool and forecasted trends<\/strong> for every seven major countries (7MM)&nbsp; from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total prevalent cases of Emphysema<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total diagnosed and treatable cases of Emphysema<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Etiology-specific cases of Emphysema<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age-specific cases of Emphysema<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Emphysema market<\/strong> or expected to get launched during the study period. The analysis covers Emphysema market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Emphysema Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/emphysema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/emphysema-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Worldwide some of the key players are diligently involved in the development of therapies for the Emphysema. Some of the therapies are in the advanced stages expected to launch in the coming years.&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Emphysema Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mereo BioPharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">United Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Emphysema Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alvelestat<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tyvaso Treprostinil&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Belimumab&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/emphysema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/emphysema-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Emphysema Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Emphysema Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Emphysema Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Emphysema Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Emphysema Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Emphysema Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Emphysema Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Emphysema Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Emphysema Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Emphysema Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Emphysema Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Emphysema Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Emphysema Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Emphysema Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Emphysema Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Emphysema Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/emphysema-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/emphysema-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pars-plantis-market\">Pars Plantis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Pars Plantis Market<\/strong>&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology, the Pars Plantis market size, and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=emphysema-market-size-share-and-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-mereo-biopharma-glaxosmithkline-united-therapeutics-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=emphysema-market-size-share-and-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-mereo-biopharma-glaxosmithkline-united-therapeutics-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Emphysema Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Emphysema Market Size and Share in the 7MM (i.e., the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/emphysema-market-size-share-and-trends-analysis-therapeutics-pipeline-outlook-and-epidemiology-insights-2032-key-companies-mereo-biopharma-glaxosmithkline-united-therapeutics-and-others_597402.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-597402","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=597402"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=597402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=597402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=597402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}